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Abstract 
 
Introduction:  Vaginal hysterectomy is considered to be the method of choice for removal of the 
uterus but most gynecologists still prefer the abdominal route for removal of benign large uteri >14 
weeks. GnRH agonists such as goserelin can reduce uterine bulk by up to 60% and was initially used 
to  convert  a  midline  to  Pfannenstiel  incision  in  abdominal  hysterectomy.  The  conversion  of  an 
abdominal to a potential vaginal hysterectomy by uterine size reduction would prove advantageous. 
 
Objective: To evaluate the efficacy of the preoperative administration of  GnRH agonist for women 
with enlarged uteri without prolapse in order to facilitate vaginal hysterectomy; in comparison with 
patients  with  enlarged uteri  who underwent to  direct Total abdominal  hysterectomy  for a similar 
indication (i.e. Menorrhagia). 
 
Design: Prospective multicentre randomized controlled trial 
 
Setting: Tertiary Center Hospitals 
 
Methods:  Women scheduled for hysterectomy for menorrhagia with non-prolapsing clinical uterine 
size  of  >14  weeks  were  offered  an  attempt  for  vaginal  hysterectomy  after  pre-treatment  with 
Goserelin for 3 months (Study group= 30).  A group of women with comparable uterine size who 
underwent abdominal hysterectomy for similar indication served as (Control group=30).  Pre- and 
postoperative  data  such  as  hemoglobin,  myoma  size,  uterine  weight,  duration  of  procedure  and 
complications, pain score, and length of hospital stay were collected prospectively. 
 
Results:  Both  groups  had  comparable  preoperative  hemoglobin,  body  mass  index  and  subjective 
preoperative uterine bulk (16.7±2.4 vs16.9±2.2 weeks). The uterine weight was lower in the study 
group (507.6±211 g) compared to the control group (728.8±189 g), P<0.001.The subjective mean 
decrease in clinical uterine bulk was 20%. The duration of surgery was nearly twice as long in vaginal 
(123.3±34.9 min) compared to abdominal hysterectomy (73.9±23.9 min), P< 0.001, but analgesia use 
and the length of inpatient stay were lower in the study group (2.4±1 days) compared to control group 
(4.97±1.5 days), P<0.001. No significant difference between the two groups as regards the rate of 
occurrence of surgical complications. 
 
Conclusions: In women with >14 week size uteri, treatment with gonadotrophin agonists reduces 
uterine size sufficiently to allow safe vaginal hysterectomy. Although duration of surgery was longer, 
women who underwent vaginal hysterectomy required less analgesia and had shorter inpatient stay. 
 
Keywords: Non-descent vaginal hysterectomy, Gonadotrophin-releasing hormone agonist. 
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Introduction 
 
In  the  US,  over  600,000  hysterectomies  are 
performed annually, making it second only to 
cesarean delivery among surgeries performed 
on women (Wu  et al. 2007). The abdominal 
approach,  the  most  commonly  performed 
(Whiteman    et  al.  2008),  carries  the  highest 
complication  rate  (Garry    et  al.  2004)  and 
imposes  the  greatest  recovery  burden  and 
highest cost (Lumsden et al 2000).  
Laparoscopic hysterectomy, potentially a less 
invasive  alternative  to  abdominal 
hysterectomy,    has  suffered  from  slow  skill 
development  (Reich  and    Robert    2003)and 
higher  complication  rates  (Altgassen    et  al. 
2004)  and  cost  as  compared  to  the  vaginal 
approach (Kovac  2000).  
Vaginal hysterectomy, with its lowest rate of 
complications,  recovery  burden,  and  costs 
(Van  Den    et  al.1998),  (Mulholland    et  al. 
1996),  might  be  considered  the  optimal 
approach.  Mindful,  the  American  College  of 
Obstetricians  and  Gynecologists,  in  its 
November 2009 Committee Opinion regarding 
hysterectomy  route  for  benign  indications 
states, “evidence demonstrates that, in general, 
vaginal hysterectomy is associated with better 
outcomes  and  fewer  complications  than 
laparoscopic  or  abdominal  hysterectomy” 
concluding  “vaginal  hysterectomy  is  the 
approach  of  choice  whenever  feasible,  based 
on its well-documented advantages and lower 
complication  rates”  (ACOG  Committee 
Opinion 2009). 
The  most  common  reason  cited  by 
gynecologists for favoring abdominal over the 
vaginal  approach  is  large  uterine  bulk,  and 
many  would  be  reluctant  to  attempt  VH  in 
patients with an estimated uterine size of 12–
14 weeks (Doucette  et al. 2001), (Synder  et 
al.  2002).  Observational  and  comparative 
studies by (Magos  et al. 1996), (Harmanli  et 
al.  2004)  and  (Sahin    2007).    However, 
demonstrated  that  uteri  of  up  to  20  weeks 
could be removed vaginally. 
GnRH  agonists  induce  a  profound  down 
regulation  of  the  pituitary  with  a  subsequent 
post  receptor  message  blockage  for 
gonadotropin synthesis and secretion. After a 
rapid  secretion  of  gonadotropins  (‘‘flare-up’’ 
effect) during the first 2 weeks of treatment, 
there is a weak inhibition of pituitary function 
with  inhibition  of  follicular  development, 
anovulation,  and  a  reversible 
hypogonadotropic  hypogonadism  state 
(Filicori  et al.1983), (Brosens  1997).  
There  are  several  protocols  for  analog 
administration  (Pickersgill    1998).  GnRH 
usually  administered  in  the  early  follicular 
phase (day 2–3 of the menstrual cycle). They 
are used preoperatively for 2 or 3 months in 
short-term protocols both to reduce fibroid and 
uterine  volume  and  to  control  bleeding, 
whereas long-term protocols (over 6 months) 
are used in perimenopausal women to induce 
an iatrogenic climacteric state in the long-term 
nonsurgical  management  of  symptomatic 
leiomyomas (Pickersgill  1998). 
Stovall  and  colleagues  have  used 
gonadotrophin-releasing  hormone  (GnRH) 
agonists as a preoperative adjunct to medically 
debulk  uteri,  thus  enabling  hysterectomy, 
which otherwise would have been approached 
abdominally,  to  be  performed  vaginally 
(Stovall  et al. 1994). 
 In this study, our purpose was to evaluate the 
efficacy of the preoperative administration of a 
GnRH agonist for women with enlarged uteri 
without prolapse in order to facilitate vaginal 
hysterectomy;  the  control  group  comprised 
patients with enlarged uteri who underwent to 
direct total abdominal hysterectomy (TAH) for 
a similar indication (i.e. menorrhagia).  
 
Patients and methods 
 
Subjects: 
 
This is a prospective study which was carried 
out  at  the  Obstetrics  and  Gynecology 
departments  of  3  tertiary  hospitals  (Medical 
Teaching  Centre-  KSA  and  Enjab  Hospital- 
UAE –Bab El sharia hospital CE) during the 
period from June 2008 to December 2011. The 
study was approved by the Ethics Committee 
of  all  hospitals.  Sixty  women  admitted  for 
hysterectomy  for  menorrhagia  were 
participated  in  the  study  and  enrolled  after 
informed  and  written  consent.  Inclusion 
criteria  included  uterine  size  ≥  14  not 
exceeding  20  weeks  of  gravid  uterus  (by 
clinical judgment), adequate access with good 
uterine  mobility.  Exclusion  criteria  included 
uterus  with  severely  restricted  mobility, 
women  with  vaginas  narrower  than  two 
fingers,  wide  suspicion  of  malignancy, Mohamed AbdElzaher…et al 
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extensive  pelvic  adhesion  and  complex 
adnexal mass. 
Randomization and Preparation: 
Patients  who  participated  in  the  study  were 
randomized  either  to  vaginal  hysterectomy 
after  preoperative  administration  goserelin 
acetate 3.6 mg (Zoladex, Astra Zeneca, Ltd.) 
intramuscular  every  4  weeks  for  3  doses, 
treatment  was  started  on  day  2  of  menstrual 
cycle.  (Study group = 30) or to direct TAH 
(control  group  =  30).  Randomization  was 
performed using a list of computer-generated 
random  numbers  and  participants  were 
assigned  to  their  groups  using  sealed 
envelopes. 
Detailed  history  and  clinical  examinations 
were  done  in  each  case.  Women  had 
preoperative clinical evaluation of uterine size 
and  mobility,  pelvic  Ultrasonography,  and 
when  indicated  diagnostic  hysteroscopy  and 
endometrial sampling. Patients were followed 
every  4  weeks  for  the  treatment  duration. 
During  treatment  each  patient  underwent 
monthly  pelvic  examination  by  the  same 
physician and repeat sonography to determine 
uterine  and  fibroid  volume.  The  baseline 
characteristics  of  the  patients  including  age, 
body  mass  index,  obstetric  history, 
menopause,  previous  surgery,  and 
preoperative  diagnosis  were  recorded  at 
admission. 
 
Surgery and post-operative follow up: 
Each  subject  received  prophylactic  antibiotic 
treatment (cefazoline 2 g intravenously) at the 
beginning  of  the  operation  and  prophylactic 
anticoagulant  therapy  with  low  molecular 
weight  heparin  the  evening  before  the 
operation, wore anti embolic stockings and/or 
sequential  compression  stockings.  All 
operations  were  performed  by  Consultants. 
VH patients had a vaginal pack and indwelling 
urinary  catheter  in  situ  until  the  following 
morning.  In  addition,  operative  time,  uterine 
weight, estimated blood loss, perioperative and 
postoperative  complications,  pain  score,  and 
length  of  hospital  stay  were  also  recorded 
before  discharge.  The  operative  time  was 
calculated from the first incision to the end of 
wound closure.  
Blood loss was estimated by summation of the 
blood  volume  aspirated  and  the  weight 
difference of the gauze used before and after 
surgery. If a blood transfusion was performed, 
the number of transfused blood was recorded. 
At the end of the surgery, the extirpated uteri 
were weighed before fixation in formalin. Pain 
was evaluated using the visual analog scoring 
(VAS)  system:  0  no  pain,  2  mild  pain,  5 
moderate pain, 7 severe pain, 10 excruciating 
(Fishman  et al. 1987). VAS is recorded every 
6 h by the nursing staff. The highest VAS on 
postoperative  day  0  and  postoperative  day  1 
was used. All patients received a standardized 
postoperative protocol of two doses of 50 mg 
of meperidine intravenously 4 h apart for pain 
control,  followed  by  500  mg  acetaminophen 
every 6 h. The complications analyzed were as 
follows:  (1)  major:  injury  to  a  major  blood 
vessel or organ (i.e., bowel, bladder, or ureter), 
hematoma  or  bleeding  of  the  vaginal  cuff 
requiring  prolongation  of  care  or  surgical 
treatment  or  (2)  minor:  febrile  morbidity 
(defined  as  two  or  more  oral 
temperatures¸38°C  occurring  more  than  6  h 
apart  excluding  first  24  h),  vaginal  cuff 
infection,  vaginal  cuff  hematoma,  pelvic 
infection,  or  urinary  tract  infection. 
Unintended  conversion  to  TAH  was  also 
noted.   
Outcome  measures for both the  groups  were 
studied  comparatively  in  terms  of  length  of 
operative  time,  amount  of  blood  loss, 
requirement  of  blood  transfusion, 
perioperative and postoperative complications, 
pain score, and length of hospital stay. 
 
Data registration and Statistical analysis:  
The  results  were  tabulated  and  statistically 
analyzed  using  a  computer  program  SPSS 
(statistic a package for social science), version 
15 software. The sample  mean (X), standard 
deviation (SD), and standard error of the mean 
as  well  as  the  range  were  obtained  for 
numerical  variables.  For  non-numerical 
variables,  the  frequency,  distribution  and 
percentage  were  calculated.  The  student's  (t) 
test  was  used  to  test  the  significance  of  the 
difference between 2 independent means.  
The  Chi  square  test  (X²)  was  used  to  test 
whether  the  distribution  of  a  certain 
phenomenon among two or more groups was 
equal  or  not.  The  probability  (P)  value  was 
calculated  and  a  P-value  <  0.05  was 
considered statistically significant.  
 
Results 
This study was performed in the period from 
June  2008  to  December  2011.  Two  hundred Is the use of gonadotrophin… 
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and  forty  women  underwent  hysterectomy 
during the study period and  only 60 patients 
were  eligible  to  enroll  in  the  study.  Patients 
were  divided  into  two  groups,  vaginal 
hysterectomy after preoperative administration 
GnRH  a  (study  group  =30)  and  direct  TAH 
(control group =30).  
Table  1.    shows  the  basic  clinical 
characteristics of the patients in both groups. 
There was no significant difference in terms of 
age, parity, body mass index, Clinical size of 
uterus, previous cesarean delivery, or previous 
pelvic surgery. 
 
Table 1: Patient characteristics   
Patient characteristics    VH (n=30)  TAH (n= 30)  P value 
Age , years  48.7±3.7  50.3±4.3  0 .116 
Parity    3.9±1.8  4.7±2.1  0 .102 
Body mass index, kg /m
2  31.1±2.2  29.7± 5.6  0 .199 
Clinical size of uterus 
(weeks) 
16.7±2.4  16.9±2.2  0 .176 
Previous  cesarean section  2 (6.7%)  3 (10%)  1.00 
Previous abdominal surgery  1 (3.4%)  2 (6.7%)  1.00 
 
Surgical characteristics are presented in Table 
2. The mean subjective uterine size of the VH 
group  prior  to  Goserelin  injections  was 
(16.7±2.4  weeks)  compared  to  (16.9±2.2 
weeks) in TAH group. On the other hand, the 
subjective uterine bulk at the time of surgery 
was  (14.07±1.4  weeks)  in  VH  group  vs. 
(16.9±2.2  weeks)  in  TAH  group  and  uterine 
weight  was  (507.6±211  g)  in  VH  group  vs. 
(728.8±189  g)  in  TAH  group;  which  were 
comparable in both groups (p<0.001 for each 
variable).The  subjective  mean  decrease  in 
clinical uterine bulk was 20%. 
The mean duration of surgery (123.3±34.9 vs. 
73.9±23.9  min)  (p<  0.001)  and  estimated 
blood loss (485.4±196.8 vs. 366.5±176.4 ml) 
(p<0.05)  were  significantly  higher  in  the 
vaginal  compared  to  the  abdominal 
hysterectomy group. Four women in VH group 
sustained a blood loss in excess of  
500 ml, three of them need blood transfusion, 
and by comparison, one woman in TAH group 
sustained a blood loss in excess of 500 ml and 
no  need  blood  transfusion  (P  >  0.05). 
Salpingo-oophorectomy was performed in two 
patients  (6.7%)  in  VH  group  and  3  patients 
(10%) TAH group (P = 1.00). 
The  mean  length  of  hospital  stay  (2.4±1  vs 
4.97±1.5  days)  (p<0.001)  were  significantly 
lower  in  the  vaginal  compared  to  the 
abdominal  hysterectomy  group.  Mean  pain 
score in postoperative  day0  was (2.6±1.8 vs. 
5.6±2.6)  and  in  postoperative  day1  (1.5±1.5 
vs. 3.1±1.5) (P< 0.001 for each variables). 
 
Table 2: Surgical characteristics 
  VH (n=30)  TAH (n= 30)  P value 
Clinical size at time of surgery 
(wk) 
 
14.07±1.4 
 
16.9±2.2 
 
0 .001 
Histological uterine weight (g)  507.6±211  728.8±189  0.001 
Operating time (min)  123.3±34.9  73.9±23.9  0.001 
Estimated blood loss ( ml)  485.4±196.8  366.5±176.4  0 .017 
Blood loss > 500 ml    4(13.4%)  1(3.4%)  0.353 
Blood transfusion (n & %)  3(10%)  0(0%)  0 .237 
Bilateral salpingo-
oophorectomy (n &%) 
2(6.7%)  3(10%)  1.00 
Length of stay (days)  2.4±1  4.97±1.5  0 .001 
Pain, day 0  2.6± 1.8  5.6±2.6  0.001 
Pain, day 1  1.5± 1.5  3.1±1.5  0.001 
Total complication (n &%)  5(16.7%)  9(30%)  0.360 
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Operative and postoperative complications are 
presented in Table 3. No significant difference 
was  noted  in  overall  complications  between 
groups (P = 0.36). One patient  in  VH group 
sustained a bladder injury; this patient had one 
previous  caesarean  section.  The  injury  was 
recognized during the operation and treated by 
trans-vaginal route with good outcome. There 
was no bowel or ureteral injury. There was no 
reopening  or  conversion  to  laparotomy,  or 
surgical mortality. All patients were followed 
up at our hospital for at least 3 months after 
surgery and all recovered uneventfully. 
 
Table 3: Complications  
  VH (n=30)  TAH (n= 30)  P value 
Major complications (n)   
Bladder injury  1(3.4%)  –  1.00 
Major vessel injury  –  1(3.4%)  1.00 
Minor complications (n)   
Vaginal cuff hematoma or 
infection 
2(6.7%)  1(3.4%)  1.00 
Urinary tract infection  –  2(6.7%)  0.492 
Febrile morbidity  1(3.4%)  2(6.7%)  1.00 
Ileus  1(3.4%)  2(6.7%)  1.00 
Respiratory infection  –  1(3.4%)  1.00 
 
Discussion 
 
It  is  a  well-known  fact  that  70%  to  80%  of 
hysterectomies  are  performed  by  abdominal 
route and vaginal approach is usually reserved 
for uterovaginal prolapse (Thomas  2007).  
The  usual  contraindications  for  vaginal 
hysterectomy  are  absence  of  significant 
uterovaginal  prolapse,  presence  of  uterine 
enlargement,  adhesions  and  the  need  for  
oophorectomy.  With  adequate  vaginal  access 
and  good  uterine  mobility,  vaginal 
hysterectomy can be easily performed.  
The  uterosacral  and  cardinal  ligaments, 
situated in close proximity to the vaginal vault 
once  clamped  and  cut  produce  first  degree 
descent.  Multiparty,  lax  tissues  following 
multiple deliveries and decreased tissue tensile 
strength  provide  comfort  to  vaginal  surgeon 
even  in  the  presence  of  uterine  enlargement. 
The  other  important  reason  for  the  lower 
proportion  of  hysterectomies  performed 
vaginally  is  the  presence  of  uterine 
enlargement  with  leiomyomas  or 
adenomyosis.  
Hysterectomy remains one of the commonest 
gynecological  operations,  and  the  Cochrane 
review  on the subject (Nieboer  et al. 2009) 
concluded  (on  the  basis  of  safety,  reduced 
postoperative  pain,  shortened  length  of  stay 
and higher patient satisfaction) that VH should 
be performed in preference to TAH, and if not 
possible,  then  a  laparoscopically  assisted 
approach may then be used.  
Furthermore, both Reich and  Garry, pioneers 
of  laparoscopic  hysterectomy,  agreed  that 
“evidence  based  studies  support  the  use  of 
vaginal  hysterectomy  if  possible  over 
laparoscopic  and  abdominal  hysterectomy” 
(Reich H 2007), (Garry R 2009).  
Despite  this,  there  is  still  reluctance  for 
gynecologists  to  perform  VH,  even  in  the 
absence of prolapse and when the uterine size 
exceeds  12  weeks.  In  fact,  only  15%  of 
hysterectomies for fibroids in the US (Lepine  
et  al.  1997)  were  performed  vaginally, 
although  many  authors  have  now  reported 
successful vaginal removal of enlarged uteri of 
up to 20 weeks (Magos  et al. 1996), (Sahin  
2007) using techniques such as bisection, Lash 
intramyometrial coring, vaginal myomectomy, 
wedge resection and debulking.  
The ACOG guidelines for hysterectomy route 
state that the choice “depends on the patient’s 
anatomy and the surgeon’s experience” and it 
is usually done in women with mobile uteri no 
larger than one at 12 weeks’ gestation (280 g) 
(American  College  of  Obstetricians  and 
Gynecologists 1989).  
Indications  for  abdominal  hysterectomy  are 
usually determined from the standard surgical 
text  (Thompson  1992).  Those  indications 
include uterine size larger than 280 g, previous 
pelvic  surgery,  and  history  of  pelvic 
inﬂammatory  disease,  endometriosis, Is the use of gonadotrophin… 
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concomitant  adnexal  masses,  and  indication 
for  adnexectomy.  However,  (Kovac    1995) 
was able to do vaginal hysterectomies in 97% 
of  women  who  had  those  presumptive  risk 
factors that are believed to mandate abdominal 
hysterectomy. 
GnRH  agonist  treatment  is  known  to  reduce 
the  volume  of  uterus  by  35-50%.  The 
reduction in myoma size is reported as a wide 
range (15-90%) with reduction in blood flow 
through the uterine vessels after GnRH agonist 
therapy  (Broekmans    1996), (Stovall    et  al. 
1994) were the first to describe the concept of 
medically  debulking  the  enlarged  uterus  to 
facilitate VH and were able to show a success 
rate  of  70%  for  uteri  between  14  and  18 
weeks.  
When translated in to cost analyses, significant 
potential savings could be made, which would 
easily compensate for the cost of preoperative 
GnRH analogues expenditure (Bradham  et al. 
1995). Previous costing by Johns et al from the 
US  (Pickersgill    1998)  indicated  that  the 
average hospital charge for VH was US $700 
less  than  TAH  (US  $5,869  vs.  $6,552)  but 
more net profit with the former because of the 
shorter duration of inpatient stay.  
While laparoscopy is a useful adjunct to VH 
when  extensive  adhesiolysis  is  contemplated 
or when there is suspected adnexal pathology, 
we concur with previous authors (Magos et al. 
1996), (Unger  1999), (Varma   et al. 2001) 
that  laparoscopic  assistance  is  not  otherwise 
necessary  for  the  vaginal  removal  of  a 
moderately enlarged uterus.  
Our study simply seeks to suggest that medical 
debulking using GnRH analogues can convert 
an abdominal to a potentially safe VH and is a 
simple and cost-effective  way through which 
"average” gynecologists can improve skill and 
confidence in attempting the vaginal route.  
Our  study  corroborates  the  previous  findings 
that the neoadjuvant use of GnRH analogues 
can  help  facilitate  vaginal  hysterectomies  in 
moderately  large  uteri  and  further 
demonstrates positive advantages compared to 
a group of patients with similar uterine size at 
surgery that underwent TAH. 
 The  mean  weight  of  uteri  removed  in  the 
present study was high above the limit of 280 
g (12 weeks’ gestation) that was recommended 
as  the  limit  for  vaginal  hysterectomy 
(American  College  of  Obstetricians  and 
Gynecologists 1989), (Kovac  1995). In most 
of cases the uterine weight was at least 500 g 
with no special difficulties.  
Therefore, as (Magos et al. 1996) concluded, 
uterine  size  by  itself  should  no  longer  be 
considered  a  contraindication  to  vaginal 
hysterectomy.  As reported (Unger JB 1999), 
(Richardson    et  al.  1995)  previous  pelvic 
surgery, mild endometriosis, history of pelvic 
inﬂammatory  disease,  or  uterine  ﬁbroids 
should  no  longer  be  regarded  as 
contraindications for vaginal surgery. 
In  the  present  study,  the  mean  duration  of 
surgery  and  estimated  blood  loss  were 
significantly higher in the vaginal compared to 
the abdominal hysterectomy group( p< 0.001, 
p<0.05) also the mean length of hospital stay 
and  mean  pain  score  in  postoperative  days 
were  significantly  lower  in  the  vaginal 
compared  to  the  abdominal  hysterectomy 
group( p<0.001). (Joan et al. 2011) resorted to 
this technique and reported similar findings.  
We were successful in removing uteri of up to 
20  weeks  pregnancy  size  vaginally  without 
any  increase  in  surgical  complications.  
Similar  findings  were  reported  by  Unger 
(Unger    1999)  who  operated  upon  uteri 
weighing 200 to 700 gm, without any increase 
in  complications  as  compared  to  abdominal 
hysterectomies. 
The  current  study  shows  no  significant 
difference between the two groups as regards 
the  rate  of  occurrence  of  surgical 
complications.  The  length  of  hospital  stay 
reported  by  (Dorsey    et  al.  1995)  was  3.5 
versus  4.5  days  for  total  vaginal  and  total 
abdominal  hysterectomy  respectively.  In  our 
study hospital stay was 2.4 versus 4.9 days for 
total vaginal and total abdominal hysterectomy 
respectively.  
In conclusion, the preoperative administration 
of  a  GnRH  agonist  to  facilitate  vaginal 
hysterectomy in women with non-descent and 
moderately enlarged uteri is safe and efficient. 
With  experience,  operative  time,  blood  loss 
and  complications  can  be  reduced 
considerably.  Thus  this  vaginal  approach 
should  be  chosen  as  a  preferred  method  of 
hysterectomy. 
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ه مدختسإ لهسي ل   نيبورتودانوجلاراقع   نومره   لاصئتسا يف ستسنيوجا   محرلا  
نع   قيرط   لأا يف لبهملا ؟رْبُكلا يطسوتم ماحر  
 *  ، رهاظلا دبع دمحم  *  ، ضوعم فرشأ  * ، يلع دمحم  **  ، روكدم لئاو  *** ريهز انح  
*  ، رهزلأا ةعماج بطلا ةيلك ةدلاولاو ءاسنلا دعاسم ذاتسأ ** ءاسنلا دعاسم ذاتسأ            ، سمش نيع ةعماج بطلا ةيلك ةدلاولاو
 ***  نداش بط ةيلك ةدلاولاو ءاسنلا دعاسم ذاتسأ .    
محرلا  لاصئتسا  ربتعي   قيرط  نع   لبهملا   لضفت  لازت  لا  ءاسنلا  ضارمأ ءابطأ مظعم  نكلو  محرلا  ةلازلإ  لضفملا  بولسلأا  
لاا لاصئتس    نع  ةلازلإ نطبلا قيرط    مرو  ديمح نم ربكا همجح   41   أ عوبس ا  .  ستسنيوجا نومره نيبورتودانوجلاراقع مادختسا   لثم  
نيليريسوج   نكمي   ضيفخت   مجح   محرلا   ةبسن ىلا   لصت   ىلإ   06   يف   ،ةئاملا   تمدختساو   يف   ةيادبلا    يضرع ىلا يلوطلا قشلا ليوحتل
ةلاح ىف   لاصئتسا   محرلا   نع   قيرط   نطبلا  ,  ليوحتل نلاا اهمدختسنو لاصئتسا   محرلا   م ن   قيرط   نطبلا    ىلا قيرط   لبهملا   ةلمتحم      
ضيفختب   مجح   محرلا   ل تبثي   هنأ   ديفم .    
ةساردلا نم فدهلا  : مييقتل   ةيلاعف   مادختسا   ورتودانوجلاراقع ب ني   نومره   ستسنيوجا    مخةضت نةم نيناةعي يةتلا تاديةسلل ةةحارجلا لبق
محرلاب   نود   طوقس    يلبهم ةيغب   ليهست   لاصئتسا   محرلا   نع   قيرط   لبهملا   ,   ةنراقملاب   عم   تاديس   لا يت   نيناعي   نم   مخضت   محرلاةب    مةتو
لاصئتسا   محرلا   نع   قيرط   نطبلا   ثمطلا ةدايز وهو يعادلا سفنب    .  
 ثحبلا جئاتنو بولسأ :    رةبكأ كريرةسلا محرةلا مةجحو ثمطلا ةدايز ببسب محرلا لاصئتسا لمعل ةلودجملا تاديسلا ةساردلا هذه يف
 نم 41  مت ىلولاا ةعومجملا نيتعومجم يلا مهمسقت مت ،عوبسا لاصئتسا   محرلا   نع   قيرط   لبهملا    ةدمل ةقبسملا ةجلاعملا دعب 3    رهشأ
نيليريسوج راقع عم  ( ةساردلا ةعومجم = 36  ) ةيناثلا ةعومجملاو   لاصئتسا   محرلا   نع   قيرط   نطبلا ( ةعومجم   بقارملا ة = 36 ) ,  عمج مت
لثم ةحارجلا دعبو لبق تانايبلا   وميهلا ج نيبول ,   نزوو   ،محرلا   ةدم   افعاضملاو ةحارجلا ءارجا  ت , و ةدم   ةماقلإا   يةف   ىفةشتسملا .   و  دةجو
أ ن   نزو     محرةةلا   لةةقأ   يةةف   قةةيرف   ةةةساردلا   ( 66700    ± 144   مةةجم  ) ةةةنراقم   ةةةعومجمب   مكحتةةلا   ( 71707    ± 471   مةةجم )   ( (P<0.001    ,
 ىلاوح كريرسلا محرلا مجح ضافخنا لدعمو 16   يةف   ةةئاملا  , تةناكو   ةدةم   ةةحارجلا   اةم   برةقي   نةم    عةض   لاةصئتسا يةف   محرةلا    نةع
 قيرط   لبهملا   ( 41303    ± 3101   ةقيقد  ) ةنراقملاب   عم   لاصئتسا   محرلا    نع قيرط   نطبلا   ( 7301    ± 1301   ةقيقد )   (  (P<0.001   ، نكل  
مادختةةسا   ا تانكةةسم  ملالآ   ةرةةتفو   ءاةةقب   ىةةضرملا   نييلخادةةلا   يةةف   تايفةةشتسملا   تةةناك   لةةقأ   يةةف   قةةيرف   ةةةساردلا   ( 101 ± 4   وي ةةم ا  ) ةةةنراقم  
ةعومجملاب   ةطباضلا   ( 1017 ± 406   اموي )    ( P<0.001 .)    
  ةةساردلا هذه نم صلخنو    : نأ   مادختةسا   ورتوداةنوجلاراقع ب ني   نوةمره   ستةسنيوجا   لةبق   ةةحارجلا   تاديةسلل   يةتلا   نيناةعي   نةم   مخةضت  
محرلاب   مجحو   محرلا   كريرسلا   ربكأ   نةم   41 عوبةسا   لةلقي   مةجح   محرةلا   اةمب   هةيف   ةةيافكلا    امةسلل   ب لاةصئتسا   نةع محرةلا   قةيرط     لةبهملا  
نوكيو   نمآ  . و اذإ   ناك   ةدم   ا لوطأ ةحارجل   كذلا تاديسلل   عضخ   لاصئتسا   محرلا   يلبهملا   نكلو   تانكسم   ملالآا    ةرةتفو   ءاةقب    ىةضرملا
يف   تايفشتسملا   تناك   لقأ ,     عم   ةربخلا ،   تقو    ةحارجلا   نادقفو   مدلا   تافعاضملاو   نكمي   نأ   ضفخت   لكشب   ريبك .  
 